English

Aktiespararna has published an interview with Attana's CEO

Report this content

In the interview, which can now be viewed via Aktiespararna's YouTube channel, the CEO, Teodor Aastrup, answers a number of questions and gives a brief introduction to Attana.

The interview was held in Swedish and answers the following questions:

  • The share issue that you are carrying out in December, how far will it take you?
  • You have previously mentioned that there is a lack of standardized methods to determine the neutralizing ability of antibodies, can you elaborate?
  • You have previously mentioned in press releases collaborations with institutions in the US, can you tell us more about how these have developed?
  • Why should one invest in your company?

The entire interview can be viewed via this link.

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Subscribe